Susan Ruel - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Susan Ruel's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Susan Ruel
Verified
Health Editor, MDedge Hematology and Oncology
New York
Beats
Biography
Susan Ruel currently serves as a hematology/oncology editor for a global medical news website (Medscape/WebMD). She has worked as an editor on the international desks of the Associated Press and United Press International and has reported from Shanghai, San Francisco, Washington, and New York. She has researched, written, and edited articles and books for the United Nations, including pieces on the Middle East, landmine proliferation, desertification, iodine deficiency syndrome, and oral rehydration therapy (in Nigeria). A cum laude graduate of Harvard with a doctoral degree in writing and literature, she is a former journalism professor (University of Delaware) who has co-authored two French books on U.S. media history. Before doctoral studies, Ruel lived and worked as a Fulbright scholar in West Africa (Sierra Leone). Six chapters excerpted from her historical novel, THE SHANGHAI FRIENDSHIP STORE, about foreign "experts" in China during the 1980s, were published online in 2019. Based in NYC, Ruel writes on topics ranging from politics and health care to music and travel for Medscape (WebMD), News-Decoder.com, Down Beat, and other outlets.
Homelessness, And Travel , Music, Health Care , Global Politics , Especially Chinese, Media , History
financial, family breaks, war, military
Content
By Susan Ruel Verified| Univadis ES Verified Editado por la Dra. Susan RuelCONCLUSIÓN PRÁCTICAAgregar daratumumab al tratamiento de mantenimiento con lenalidomida después del trasplante en los pacientes con mieloma múltiple triplica la tasa de conversión de enfermedad residual mínima a negativa al 50,5 % frente al 18,8 % con lenalidomida sola. Con el tratamiento combinado se reduce el riesgo de progresión en un 47 % y se logran tasas estimadas de supervivencia libre de progresión a 30 meses del 82,7 % frente al 66,4 % con lenalidomida sola.
By Susan Ruel Verified| MDEdge Verified TOPLINE:The analysis of 11,427 US Deparment of Veterans Affairs (VA) hospital patients with multiple myeloma (MM) reveals that lymphopenia affects 53% of patients at diagnosis. The median overall survival was 2.7 years in patients with severely low absolute lymphocyte count vs 4.2 years in those with normal counts.
By Susan Ruel Verified| MDedge Hematology and Oncology Verified TOPLINE:In a retrospective study of 315 patients with relapsed/refractory multiple myeloma, retreatment with previously refractory drugs achieved an overall response rate of 56.2% and median progression-free survival of 11 months. Longer initial therapy duration and greater time gap between treatments were associated with superior outcomes.
Company Info
MDedge Hematology and Oncology